ritanserin has been researched along with Parkinson Disease in 3 studies
Ritanserin: A selective and potent serotonin-2 antagonist that is effective in the treatment of a variety of syndromes related to anxiety and depression. The drug also improves the subjective quality of sleep and decreases portal pressure.
ritanserin : A thiazolopyrimidine that is 5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one which is substituted at position 7 by a methyl group and at position 6 by a 2-{4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl}ethyl group. A potent and long-acting seratonin (5-hydroxytryptamine, 5-HT) antagonist of the subtype 5-HT2 (Ki = 0.39 nM), it is used in the treatment of a variety of disorders including anxiety, depression and schizophrenia. It has little sedative action.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, S | 1 |
| Zhang, QJ | 1 |
| Liu, J | 1 |
| Ali, U | 1 |
| Wu, ZH | 1 |
| Chen, L | 1 |
| Gui, ZH | 1 |
| Wang, Y | 1 |
| Hui, YP | 1 |
| Henderson, J | 1 |
| Yiannikas, C | 1 |
| Graham, JS | 1 |
| Maertens de Noordhout, A | 1 |
| Delwaide, PJ | 1 |
3 other studies available for ritanserin and Parkinson Disease
| Article | Year |
|---|---|
In vivo effects of activation and blockade of 5-HT(2A/2C) receptors in the firing activity of pyramidal neurons of medial prefrontal cortex in a rodent model of Parkinson's disease.
Topics: Action Potentials; Amphetamines; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; | 2009 |
Effect of ritanserin, a highly selective 5-HT2 receptor antagonist, on Parkinson's disease.
Topics: Aged; Female; Gait; Humans; Male; Middle Aged; Motor Activity; Parkinson Disease; Ritanserin; Seroto | 1992 |
Open pilot trial of ritanserin in parkinsonism.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Pilot Pro | 1986 |